Company
4 developments in the corpus
Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Latest
Everything in the corpus, newest first.
AUG 14, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval action establishing Risk Evaluation and Mitigation Strategy (REMS) requirements for buprenorphine hydrochloride sublingual tablets; does not report clinical trial outcomes.
JUN 18, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
This is an FDA supplemental approval action establishing a Risk Evaluation and Mitigation Strategy (REMS) for meperidine hydrochloride; it is a regulatory classification, not a clinical evidence assessment.
JUN 18, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval of a Risk Evaluation and Mitigation Strategy (REMS) for meperidine hydrochloride; this is a regulatory action record without clinical trial data.
MAY 27, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval for labeling change to methotrexate tablet formulations; documents regulatory action only, not clinical trial data.